- Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
-
Lee CL, Chang YH, Liu CY, Hsieh ML, Huang LK, Chu YC, Kan HC, Lin PH, Yu KJ, Chuang CK, Wu CT, Pang ST, Shao IH
- KMID: 2532888
- Investig Clin Urol.
- 2022 Sep;63(5):546-553.
- doi: 10.4111/icu.20210450
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. Abiraterone acetate (AA), enzalutamide, and chemotherapy are first-line treatments for patients with mCRPC. This study examined prognostic factors for AA... -
- CITED
-
- Close
- SHARE
-
- Close
